RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $82
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $87 to $82.
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $87 to $82.